so we would be looking at fast track or accelerated approval. Orphan drug status only if tested out on rare (less than 200,000 diagnosed people) diagnosis. Perhaps some of the cancers kevetrin is being tested on will be rare enough for the orphan drug status? Either way - with even moderate efficacy this drug may move fast.